About Dr Ashish Misra

Our goal is to identify and gain insights from the genetic and molecular pathways involving in cardiovascular disorders and exploit these pathways for therapeutic benefit.

The main objective of our research program is to broaden our understanding of the cellular and molecular mechanisms involved in blood vessel wall patterning and define the role of these pathways in vascular abnormalities and complications, and then link these insights to translational research to improve the prevention and treatment of human cardiovascular disease. To this end, we employ a unique blending of mouse models, cultured cells as well as human samples, that are aimed at unveiling the pathogenesis of cardiovascular diseases. Our ultimate goal is to prevent and reverse vascular disease to prevent heart attack and stroke. I direct one of the leading cardiovascular genetics labs nationally, which is renowned for its advanced lineage tracing and atherosclerosis mouse models. These techniques are at the forefront of the field and are fundamental to perform my research. My main focus is on providing new tools and new mouse models for translational medicine, relevant to the topic of cardiovascular disease.

Dr. Ashish Misra leads the Atherosclerosis and Vascular Remodelling Group (AVRG) at Heart Research Institute (HRI) focusses on basic and translational research in vascular disease. He also holds a conjoint appointment as a senior lecturer at University of Western Australia (UWA), Perth. He did PhD at Nanyang Technological University, Singapore on Actin cytoskeleton and its role in cell migration and adhesion. Subsequently, he was awarded a prestigious Brown-Cox postdoctoral fellowship by Yale School of Medicine, Yale University to perform Postdoctoral fellowship on Cardiovascular genetics. Using advanced genetic techniques, he identified an unique population of cells that respond to hyperlipidemic conditions and clonally expand in atherosclerosis. This research has had significant scientific impact, with key publications in Nature Commun, 2018, Journal Exp Med, 2016, Sci Transl Med, 2015. With national and international collaborations, his group is currently working on identifying novel cellular and biological pathways to prevent and reverse vascular disease.

Impact of my research: Currently available cardiovascular therapies are not universally effective and do not reverse the vascular disease completely, therefore vascular diseases place a heavy burden on the health care system. Our ultimate mission is to identify the factors and signaling mechanisms that may provide better therapeutic options to eradicate cardiovascular disease.

Selected publications

1. Colchicine inhibits neutrophil extracellular trap formation in acute coronary syndrome patients post percutaneous coronary intervention. Vaidya K, Tucker B, Kurup R, Khandkar C, Pandzic E, Barraclough J, Machet J, Misra A, Kavurma M, Martinez G, Rye KA, Cochran BJ, Pate S. J Am Heart Assoc, January 2020 (Accepted).

2. ‘Translational research in culture: AADCA, diabetes and cardiovascular disease'. Misra A, Fisher EA, Cell stem cell, 2020 Jul 2;27(1):6-7. doi: 10.1016/j.stem.2020.06.012.

3. Vascular transcriptome landscape of Trail-/- mice: implications and therapeutic strategies for diabetic vascular disease. Cartland SP, Lin RCY, Genner S, Patil MS, Martínez GJ, Barraclough JY, Gloss B, Misra A, Patel S, Kavurma MM. FASEB J. 2020 Jun 5;. doi: 10.1096/fj.201902785R. [Epub ahead of print] PubMed PMID: 32501591.

4. Colchicine as a Novel Therapy for Suppressing Chemokine Production in Patients with an Acute Coronary Syndrome: A Pilot Study. Tucker B, Kurup R, Barraclough J, Henriquez R, Cartland S, Arnott C, Misra A, Martínez G, Kavurma M, Patel S. Clin Ther. 2019 Oct;41(10):2172-2181.

5. Macrophages and T cells in atherosclerosis: a translational perspective. Bartlett B, Ludewick HP, Misra A, Lee S, Dwivedi G. Am J Physiol Heart Circ Physiol. 2019 Aug 1;317(2):H375-H386.

6. Integrin beta3 regulates clonality and fate of smooth muscle-derived atherosclerotic plaque cells. Misra A, Feng Z, Chandran RR, Kabir I, Rotllan N, Aryal B, Sheikh AQ, Ding L, Qin L, Fernández-Hernando C, Tellides G, Greif DM. Nat Commun. 2018 May 25;9(1):2073. doi: 10.1038/s41467-018-04447-7. PubMed PMID: 29802249; PubMed Central PMCID: PMC5970166

7. Integrin β3 inhibition is a therapeutic strategy for supravalvular aortic stenosis. Misra A, Sheikh AQ, Kumar A, Luo J, Zhang J, Hinton RB, Smoot L, Kaplan P, Urban Z, Qyang Y, Tellides G, Greif DM.J Exp Med. 2016 Mar 7;213(3):451-63. doi: 10.1084/jem.20150688. Epub 2016 Feb 8. PubMed PMID: 26858344;

8. Smooth muscle cell progenitors are primed to muscularize in pulmonary hypertension. Sheikh AQ, Misra A, Rosas IO, Adams RH, Greif DM. Sci Transl Med. 2015 Oct 7;7(308):308ra159. doi: 10.1126/scitranslmed.aaa9712. PubMed PMID: 26446956; PubMed Central PMCID: PMC4629985.